Matthias J. Bahr

Matthias J. Bahr

Auto-generated profile, based on publicly available information

Matthias J. Bahr

Department of Neurology, University Medical Center Göttingen, Germany

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2009 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SMSarwa Darwish Murad
Sarwa Darwish Murad
APAurelie Plessier
Aurelie Plessier
MHManuel Hernández-Guerra
Manuel Hernández-Guerra
FFFederica Fabris
Federica Fabris
CEChundamannil E. Eapen
Chundamannil E. Eapen
FLFor En-Vie (European Network For Vascular Disorders Of The Liver)
For En-Vie (European Network For Vascular Disorders Of The Liver)
The Budd–Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. To characterize the causes and treatment of incident BCS. Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84%) had at least 1 thrombotic risk factor, and many (46%) had more than 1; the most common was myeloproliferative disorders (49% of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86%]), transjugular intrahepatic portosystemic shunting (56 patients [34%]), or liver transplantation (20 patients [12%]), and 80 patients (49%) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI, 75% to 88%) at 2 years. Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Fifth Framework Programme of the European Commission.

1 October 2010 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MMMichael Manns
Michael Manns
MWMarek Woynarowski
Marek Woynarowski
WKWolfgang Kreisel
Wolfgang Kreisel
YLYoav Lurie
Yoav Lurie
CRChristian Rust
Christian Rust
CSChristian P. Strassburg
Christian P. Strassburg

1 August 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
RLRalf Lichtinghagen
Ralf Lichtinghagen
DPDaniel Pietsch
Daniel Pietsch
HBHeike Bantel
Heike Bantel
MMMichael P. Manns
Michael P. Manns
KBKorbinian Brand
Korbinian Brand
MBMatthias J. Bahr
Matthias J. Bahr

5 January 2010 in Circulation
Verified
Journal Article
Closed access
PDF file
SSSajoscha A. Sorrentino
Sajoscha A. Sorrentino
CBChristian Besler
Christian Besler
LRLucia Rohrer
Lucia Rohrer
MMMartin Meyer
Martin Meyer
KHKathrin Heinrich
Kathrin Heinrich
ULUlf Landmesser
Ulf Landmesser
Background— High-density lipoprotein (HDL)–raising therapies are currently under intense evaluation, but the effects of HDL may be highly heterogeneous. We therefore compared the endothelial effects of HDL from healthy subjects and from patients with type 2 diabetes mellitus and low HDL (meeting the criteria for metabolic syndrome), who are frequently considered for HDL-raising therapies. Moreover, in diabetic patients, we examined the impact of extended-release (ER) niacin therapy on the endothelial effects of HDL. Methods and Results— HDL was isolated from healthy subjects (n=10) and patients with type 2 diabetes (n=33) by sequential ultracentrifugation. Effects of HDL on endothelial nitric oxide and superoxide production were characterized by electron spin resonance spectroscopy analysis. Effects of HDL on endothelium-dependent vasodilation and early endothelial progenitor cell–mediated endothelial repair were examined. Patients with diabetes were randomized to a 3-month therapy with ER niacin (1500 mg/d) or placebo, and endothelial effects of HDL were characterized. HDL from healthy subjects stimulated endothelial nitric oxide production, reduced endothelial oxidant stress, and improved endothelium-dependent vasodilation and early endothelial progenitor cell–mediated endothelial repair. In contrast, these beneficial endothelial effects of HDL were not observed in HDL from diabetic patients, which suggests markedly impaired endothelial-protective properties of HDL. ER niacin therapy improved the capacity of HDL to stimulate endothelial nitric oxide, to reduce superoxide production, and to promote endothelial progenitor cell–mediated endothelial repair. Further measurements suggested increased lipid oxidation of HDL in diabetic patients, and a reduction after ER niacin therapy. Conclusions— HDL from patients with type 2 diabetes mellitus and metabolic syndrome has substantially impaired endothelial-protective effects compared with HDL from healthy subjects. ER niacin therapy not only increases HDL plasma levels but markedly improves endothelial-protective functions of HDL in these patients, which is potentially more important. Clinical Trial Registration— clinicaltrials.gov. Identifier: NCT00346970.

1 December 2003 in Journal of Hepatology
Verified
Journal Article
Closed access
KRKinan Rifai
Kinan Rifai
TEThomas Ernst
Thomas Ernst
UKUlrich Kretschmer
Ulrich Kretschmer
MBMatthias J Bahr
Matthias J Bahr
ASAndrea Schneider
Andrea Schneider
DFDanilo Fliser
Danilo Fliser

1 February 2004 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
JKJan T Kielstein
Jan T Kielstein
UKUlrich Kretschmer
Ulrich Kretschmer
TEThomas Ernst
Thomas Ernst
CHCarsten Hafer
Carsten Hafer
MBMatthias J Bahr
Matthias J Bahr
DFDanilo Fliser
Danilo Fliser